Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galapagos NV (GLPG) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Galapagos files current reports on Form 6-K, which typically furnish press releases and other information to the U.S. Securities and Exchange Commission. These reports often incorporate company announcements by reference into Galapagos’ registration statements on Form S-8, reflecting updates relevant to its equity compensation plans.
Through these filings, investors can follow how Galapagos communicates material information about its biotechnology business in oncology, immunology, inflammation, fibrosis, and other indications. The 6-Ks referenced in the record indicate that Galapagos issues press releases on topics such as clinical programs, collaborations, and corporate developments, and then submits those releases to the SEC. The filings also identify Galapagos NV as having its principal executive office in Mechelen, Belgium and clarify whether the company files under Form 20-F or Form 40-F reporting frameworks.
On Stock Titan, each new GLPG filing is captured as it becomes available from EDGAR, and AI-powered tools summarize the key points of lengthy documents. Users can quickly see what a particular 6-K press release covers without reading every page, and can navigate to the underlying exhibits for full details. Over time, this page forms a chronological record of Galapagos’ SEC reporting, helping investors review how the company’s pipeline, collaborations, and strategic decisions have been communicated to the market.
For anyone researching GLPG, this filings archive offers a structured way to examine regulatory disclosures alongside AI-generated highlights, making it easier to understand the context and content of Galapagos NV’s ongoing SEC reporting.
Galapagos NV (GLPG) furnished a Form 6‑K as a foreign private issuer. The report attaches a press release dated October 23, 2025 as Exhibit 99.1 and incorporates it by reference into the company’s Registration Statements on Form S‑8.
The company indicates it files annual reports under cover of Form 20‑F. The Form 6‑K was signed by Company Secretary Annelies Denecker on October 24, 2025.
Galapagos NV filed a Form 6-K as a foreign private issuer, stating that it reports under Form 20-F. The company furnished a press release dated October 21, 2025 as Exhibit 99.1, and specified that the information in this report, except for certain quoted statements, is incorporated by reference into multiple existing employee share plan registration statements on Form S-8.
Galapagos NV furnished a Form 6-K and attached a press release dated October 16, 2025 as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, except for quotes by Henry Gosebruch and Fred Blakeslee, is incorporated by reference into its Registration Statements on Form S-8. Galapagos files annual reports on Form 20-F.
EcoR1 Capital files Amendment No. 3 to Schedule 13D on Galapagos NV (GLPG). The biotech-focused hedge fund and its founder Oleg Nodelman now report beneficial ownership of 8,714,522 ordinary shares/ADSs, equal to 13.22 % of the 65,897,071 shares outstanding (Form 20-F, 31 Dec 2024). The position is concentrated in EcoR1 Capital Fund Qualified, L.P. (8.19 m shares, 12.43 %) while EcoR1 Capital Fund, L.P. holds 0.52 m shares (0.79 %).
The shares were accumulated for an aggregate US$399.4 million; an additional US$293,693 in fees was paid to Citibank for converting ADSs into ordinary shares. EcoR1 and Mr Nodelman have shared voting and dispositive power over the entire stake.
Apart from updating share totals and cost, the filing makes no changes to the previously stated purpose of the investment or to any contracts, arrangements or relationships with the issuer. Exhibit 99.2 details trades executed in the past 60 days; no other transactions were disclosed.